PLK2 and glioblastoma: Alafate et al. (2020) reported that loss of PLK2 can enhance aggressive biological behavior of GBM through activation of Notch signaling, indicating that PLK2 may be a potential therapeutic target for GBM. Researchers used tyrosine to modify the small linear PEI, which showed good physical and chemical properties and high biocompatibility. The tyrosine-modified PEI and PLK2 siRNA complexes have shown anti-tumor effects in mouse xenografts and patient-derived xenografts models (Karimov et al., 2021).